Drug intelligence / Profile preview

Calonest

Development stage: Unknown
Lead developer: Prisure Medicare
Modality: Small Molecules
Administration: Oral

Overview

**Calonest** is an oral fixed-dose mineral and vitamin formulation marketed by Prisure Medicare for nutritional deficiencies and bone-health support. The tablet contains calcium citrate, cholecalciferol, magnesium, and zinc; it is intended to support calcium and vitamin D replacement, bone mineralization, skeletal strength, and maintenance of normal muscle and nerve function. Public product listings describe use in calcium and vitamin D deficiency and bone disorders, including osteoporosis support. ([pharmeasy.in](https://pharmeasy.in/online-medicine-order/calonest-tab-15-s-210395))

Brand names: Calonest
Other names: Calonest TabCalonest Tablet

Beyond the preview

Go deeper on Calonest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calonest.

Explore the full profile